Biofarma Positioning For Growth in Turkish Market
This article was originally published in PharmAsia News
Biofarma, one of the dynamic actors in the challenging Turkish pharmaceutical market, put up a strong performance in 2012–13 and its owners are now looking to benefit. So far, information on a likely share sale by one or both of the firm’s two investors has not been released, but Biofarma is looking forward to new opportunities and as sales and marketing director Gurhan Kaba told PharmAsia News in an exclusive interview, “Biofarma is a platform ready to grow.”
You may also be interested in...
GlaxoSmithKline PLC is rumored to be among three final bidders for Turkish generic drug maker Biofarma Pharmaceutical Industry Co. Inc. MNCs in Turkey are stepping up plans to establish a local manufacturing presence in Turkey to respond to continued price pressure, according to analysts
Late payment of hospital debts continues to haunt the Turkish medtech industry, which recently led a public demonstration in Ankara to focus the government’s attention on the issue. Medtech multinationals fear that the ongoing problems will mean Turkey losing the positive momentum it achieved during the pandemic.
One Hurdle After Another: Safely Aligned With EU MDR, Turkish Medtechs Brace For New Efforts On Domestic Front
Alignment with the MDR gave Turkish medtech access to the EU market, but in domestic pricing, costs, reimbursement and payment of hospital debts, industry might feel it is barely at the starting line.